Clinical-stage biotechnology company MaaT Pharma (EURONEXT: MAAT) announced on Monday that it has commenced its Phase 2b trial, named PHOEBUS, assessing MaaT033, a donor-derived microbiome therapy capsule, as an adjunctive treatment for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients with blood cancer.
This international, randomised, double-blind, placebo-controlled study, set to enroll 387 patients across 56 clinical sites, is reportedly the largest of its kind in oncology microbiome therapy.
Regulatory approvals have been secured in France and Germany, with further expansion planned pending additional regulatory clearance.
PHOEBUS aims to evaluate the efficacy of MaaT033 in improving 12-month overall survival rates for allo-HSCT patients. The primary endpoint is overall survival, to be assessed in late 2026. Secondary endpoints include safety and tolerability assessments before and after allo-HSCT, as well as evaluating engraftment of beneficial microbial species from MaaT033.
MaaT033, MaaT Pharma's second drug candidate, is an oral Microbiome Ecosystem TherapyTM designed for ambulatory care. It contains anti-inflammatory ButycoreTM species and targets optimal microbiota function. The drug, granted Orphan Drug Designation by the European Medicines Agency in August 2023, addresses the impact of harsh conditioning treatments on the gut microbiome during allo-HSCT, potentially improving patient survival rates.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating liquid tumours. However, the associated conditioning treatments can harm the gut microbiome, leading to decreased survival, increased graft-vs-host disease risk and infections. In 2021, nearly 20,000 allo-HSCT transplantations were reported in Europe, with continued growth.
MaaT Pharma is dedicated to restoring patient-microbiome symbiosis in oncology. Beyond the PHOEBUS trial, the company has initiated a Phase 3 clinical trial for acute graft-vs-host disease (GvHD). Its gutPrint discovery and analysis platform enables target identification, drug evaluation and biomarker identification for microbiome-related conditions. The company ensures cGMP manufacturing and quality control for its Microbiome Ecosystem Therapies, providing a diverse microbiome in liquid and oral formulations. MaaT Pharma collaborates with world-leading scientists and regulators to integrate microbiome therapies into clinical practice.
Redwire partners with Bristol Myers Squibb for space-based drug research
Bruker unveils USD100 deep plasma proteomics solution
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)